50% of U.S. News & World Report’s “Best Hospitals”
for Cardiology & Heart Surgery Making the
SynCardia Total Artificial Heart Part of Their Toolbox
Among the Top 50 Hospitals, 15 are SynCardia Certified Centers,
5 are Currently Completing Certification and 5 are Starting Certification
TUCSON, Ariz. – July 19, 2012 – SynCardia Systems, Inc., manufacturer of the world’s first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that among the top 50 centers honored in U.S. News & World Report’s “Best Hospitals” list for cardiology and heart surgery, 15 are certified to implant the SynCardia temporary Total Artificial Heart, five are currently completing certification and an additional five are starting certification.
“The U.S. News and World Report rankings are a clear indicator that the SynCardia Total Artificial Heart is rapidly becoming the new standard of care for end-stage biventricular heart failure,” said Michael Garippa, SynCardia Chairman/CEO/President.
During Q1 2012, SynCardia Certified Centers set a new record for Total Artificial Heart implants performed in a single quarter. Through the first half of 2012, implants have increased by 48% compared to the same period last year. There are currently 34 SynCardia Certified Centers in U.S. and 67 worldwide.
In June, U.S. News and World Report published a list of the “Best Children’s Hospitals” for cardiology and heart surgery. Among the top 10 were three pediatric centers that offer the SynCardia Total Artificial Heart: The Children's Hospital of Philadelphia (CHOP) ranked #2, Texas Children's Hospital ranked #3 and Cincinnati Children's Hospital Medical Center ranked #9. Several additional top pediatric centers are planning to add the Total Artificial Heart to their programs by the end of the year.
Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for patients suffering from end-stage heart failure affecting both sides of the heart (biventricular failure). There have been more than 1,000 implants of the Total Artificial Heart, accounting for more than 270 patient years of life.
About SynCardia Systems, LLC
SynCardia Systems, LLC in Tucson, Ariz., is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. For people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure), the SynCardia temporary Total Artificial Heart is used as a bridge to transplant, helping them survive until a matching donor heart becomes available. SynCardia also manufactures the Freedom® portable driver, which powers the SynCardia Total Artificial Heart and allows clinically stable patients to be discharged from the hospital to enjoy life at home while they wait for a heart transplant.
Janelle Drumwright, firstname.lastname@example.org, (520) 547-7463